Administration of Interleukin 12 With Pulse Interleukin 2 and the Rapid and Complete Eradication of Murine Renal Carcinoma

Jon M. Wigginton(Bristol-Myers Squibb (United States)), Robert H. Wiltrout(Frederick National Laboratory for Cancer Research), Timothy Back(Science Applications International Corporation (United States)), Jeferson Luís Franco(Frederick National Laboratory for Cancer Research), Kristin L. Komschlies(Science Applications International Corporation (United States)), Michael J. Brunda(La Roche College)
JNCI Journal of the National Cancer Institute
January 3, 1996
10.1093/jnci/88.1.38
Cited by 160

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k